Patents by Inventor Mark Thursz

Mark Thursz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Clinical diagnosis of non-alcoholic fatty liver disease using a panel of human blood protein biomarkers
    Patent number: 12130293
    Abstract: The invention relates to methods of diagnosing, prognosing, or monitoring or staging the progression of non-alcoholic fatty liver disease (NAFLD) using biomarkers. The invention also relates to a method of scoring to determine the severity of NAFLD, and a method of treating NAFLD.
    Type: Grant
    Filed: May 17, 2022
    Date of Patent: October 29, 2024
    Assignee: SHOX SCIENCE LIMITED
    Inventors: Bevin Gangadharan, Abhinav Kumar, Raymond A. Dwek, Nicole Zitzmann, Mark Thursz, Jeremy Francis Lars Cobbold
  • CLINICAL DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE USING A PANEL OF HUMAN BLOOD PROTEIN BIOMARKERS
    Publication number: 20230117596
    Abstract: The invention relates to methods of diagnosing, prognosing, or monitoring or staging the progression of non-alcoholic fatty liver disease (NAFLD) using biomarkers. The invention also relates to a method of scoring to determine the severity of NAFLD, and a method of treating NAFLD.
    Type: Application
    Filed: May 17, 2022
    Publication date: April 20, 2023
    Inventors: Bevin GANGADHARAN, Abhinav KUMAR, Raymond A. DWEK, Nicole ZITZMANN, Mark THURSZ, Jeremy Francis Lars COBBOLD
  • Clinical diagnosis of non-alcoholic fatty liver disease using a panel of human blood protein biomarkers
    Patent number: 11366124
    Abstract: The invention relates to methods of diagnosing, prognosing, or monitoring or staging the progression of non-alcoholic fatty liver disease (NAFLD) using biomarkers. The invention also relates to a method of scoring to determine the severity of NAFLD, and a method of treating NAFLD.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: June 21, 2022
    Assignee: ShOx Science Limited
    Inventors: Bevin Gangadharan, Abhinav Kumar, Raymond A. Dwek, Nicole Zitzmann, Mark Thursz, Jeremy Francis Lars Cobbold
  • CLINICAL DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE USING A PANEL OF HUMAN BLOOD PROTEIN BIOMARKERS
    Publication number: 20190339288
    Abstract: The invention relates to methods of diagnosing, prognosing, or monitoring or staging the progression of non-alcoholic fatty liver disease (NAFLD) using biomarkers. The invention also relates to a method of scoring to determine the severity of NAFLD, and a method of treating NAFLD.
    Type: Application
    Filed: August 23, 2017
    Publication date: November 7, 2019
    Inventors: Bevin GANGADHARAN, Abhinav KUMAR, Raymond A. DWEK, Nicole ZITZMANN, Mark THURSZ, Jeremy Francis Lars COBBOLD
  • LIVER INFECTION
    Publication number: 20160377599
    Abstract: The invention relates to a method for studying an infection process in liver tissue in vitro, the method comprising: seeding hepatocyte cells onto a scaffold in a bioreactor in order to form a liver tissue model;delivering an infectious agent to the liver tissue model, or providing the liver tissue model pre-infected with an infectious agent; and monitoring the infection process; and a method for producing an infectious agent.
    Type: Application
    Filed: July 11, 2014
    Publication date: December 29, 2016
    Inventors: David Hughes, Cliff Rowe, Emma Large, Mark Thursz, Marcus Dorner
  • Methods of treatment and diagnosis of patients with hepatitis c infection
    Publication number: 20060257850
    Abstract: Use of a compound capable of modulating the level of activity of the OAS gene and/or activity of the OAS protein, in the manufacture of a medicament for the treatment of a patient with or at risk of hepatitis C infection, wherein the compound is not an interferon or an isoprenoid, such as geranylgeranylacetone (GGA). A method of screening for compounds for treating HCV infection, wherein a cell is treated with a test compound and any change in OAS gene activity and/or OAS protein activity or level is assessed, wherein the compound is not an interferon or an isoprenoid, such as geranylgeranylacetone (GGA). Use of a compound capable of modulating the level of activity of the RNAse L gene and/or activity of the RNAse L protein, in the manufacture of a medicament for the treatment of a patient with or at risk of hepatitis C infection, wherein the compound is not an interferon or an isoprenoid, such as geranylgeranylacetone (GGA).
    Type: Application
    Filed: April 15, 2003
    Publication date: November 16, 2006
    Inventors: Adrian Hill, Mark Thursz, Susanne Knapp